ITA5019
ITA5019
- Catalog: ITA5019
- Gene/Protein: LILRA2
- Product Description: Immunotag™ LILRA2 Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | LILRA2 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500~1:1000, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide |
| Specificity | LILRA2 Antibody detects endogenous levels of total LILRA2 |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | LILRA2 |
| Accession No. | Q8N149 |
| Alternate Names | CD85 antigen-like family member H; CD85h; ILT-1; ILT1; Immunoglobulin like transcript 1; Immunoglobulin-like transcript 1; Leukocyte immunoglobulin like receptor 7; Leukocyte immunoglobulin like receptor subfamily A member 2; Leukocyte immunoglobulin-like receptor 7; Leukocyte immunoglobulin-like receptor subfamily A member 2; LILRA2; LIR-7; LIR7; LIRA2_HUMAN; |
| Description | Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061). |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 53 KD |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|